1. Executive Summary
2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Introduction
2.1. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Taxonomy
2.2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market –Definitions
2.2.1. Drugs
2.2.2. Route of Administration
2.2.3. Trial Phase
3. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis
3.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Competition Landscape
3.7. Epidemiology
4. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market opportunity analysis
5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market, By Drugs, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1. Interferon Beta-1a
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Imatinib
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Sivelestat
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. L-Citrulline
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Poractantalfa
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Ganciclovir
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration,2013 – 2017 and Forecast, 2017 – 2024
6.1. Oral
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1. Preclinical Trials
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Phase 1
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Phase 2
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Phase 3
7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Phase 4
7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
9. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Interferon Beta-1a
9.1.2. Imatinib
9.1.3. Sivelestat
9.1.4. L-Citrulline
9.1.5. Poractantalfa
9.1.6. Ganciclovir
9.1.7. Others
9.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Preclinical Trials
9.3.2. Phase 1
9.3.3. Phase 2
9.3.4. Phase 3
9.3.5. Phase 4
9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
9.6. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
10. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
10.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Interferon Beta-1a
10.1.2. Imatinib
10.1.3. Sivelestat
10.1.4. L-Citrulline
10.1.5. Poractantalfa
10.1.6. Ganciclovir
10.1.7. Others
10.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Preclinical Trials
10.3.2. Phase 1
10.3.3. Phase 2
10.3.4. Phase 3
10.3.5. Phase 4
10.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
10.6. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
11. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
11.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Interferon Beta-1a
11.1.2. Imatinib
11.1.3. Sivelestat
11.1.4. L-Citrulline
11.1.5. Poractantalfa
11.1.6. Ganciclovir
11.1.7. Others
11.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Preclinical Trials
11.3.2. Phase 1
11.3.3. Phase 2
11.3.4. Phase 3
11.3.5. Phase 4
11.4. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
11.6. Asia-PacificAcute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
12. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
12.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Interferon Beta-1a
12.1.2. Imatinib
12.1.3. Sivelestat
12.1.4. L-Citrulline
12.1.5. Poractantalfa
12.1.6. Ganciclovir
12.1.7. Others
12.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Preclinical Trials
12.3.2. Phase 1
12.3.3. Phase 2
12.3.4. Phase 3
12.3.5. Phase 4
12.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
12.6. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
13. Middle East and Africa Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
13.1. Drugs Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Interferon Beta-1a
13.1.2. Imatinib
13.1.3. Sivelestat
13.1.4. L-Citrulline
13.1.5. Poractantalfa
13.1.6. Ganciclovir
13.1.7. Others
13.2. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.3. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Preclinical Trials
13.3.2. Phase 1
13.3.3. Phase 2
13.3.4. Phase 3
13.3.5. Phase 4
13.4. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
13.6. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AltorBioScience
14.2.2. Genentech, Inc.
14.2.3. Faron Pharmaceuticals Ltd.
14.2.4. AltorBioScience
14.2.5. Suntory Pharmaceutical
14.2.6. Eli Lilly and Company
14.2.7. Asklepion Pharmaceuticals, LLC
14.2.8. BioMarck Pharmaceuticals, Ltd.
14.2.9. Others
15. Research Methodology
16. Key Assumptions and Acronyms